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THE influence of adrenal cortical hormone on the connective tissue has been
observed by some investigators. It was reported that cortisone acetate depressed
sulphate (Na235SO4) incorporation into chondroitin sulphate and carbon (acetate-
1-14C) incorporation into chondroitin sulphate and hyaluronic acid of rat skin
(Schiller and Dorfman, 1957), and that a short period of elevated plasma corti-
costerone-levels caused a decrease in hyaluronic acid and chondroitin sulphate and
in diffusibility of intradermally injected colloidal particles in rat skin (Fediay
and Clay, 1964). At the same time, the inhibitory effect of adrenal cortical
hormones on the growth of tumours has recently been studied by many workers
(Watson, 1958; Moore, Kondo and Oliver, 1960; Kodama, 1962). The present
author demonstrated the age and sex differences in inhibitory effect of hydro-
cortisone acetate on the growth of solid Ehrlich ascites tumour in SM mice
(Takeuchi, Kano and Tauchi, 1965).
On the other hand, the present author (Takeuchi, 1965, 1966) has recently
discovered the growth-promoting activity of chondroitin sulphate-an important
component of the connective tissue ground substance-in the system of solid
Ehrlich ascites tumour.
In order to elucidate the mechanisms of promoting activity of chondroitin
sulphate on the growth of Ehrlich tumour, the influence ofhydrocortisone acetate
upon the activity ofchondroitin sulphate has been investigated in terms oftumour
growth and some of the findings are presented here.
MATERIALS AND METHODS
The animals used throughout this experiment were male SM inbred mice
70-100 days old, obtained from the Supplying Centre of Laboratory Animals in
this medical school. They were fed with a pellet diet (CA-1, Nihon Clea Co..
Ltd., Tokyo) and given drinking water ad libitum.
The tumour cells used in this study were Ehrlich hypotetraploid stock Kazi-
wara 4N (Kaziwara, 1954) maintained in adult male SM mice through serial
intraperitoneal transplantation at 7 or 8 day intervals in this laboratory.
Two per cent chondroitin sulphate C solution (Av. Mol. Wt., 50.000,; Kaken
Yakukako Co. Ltd., Tokyo) was subcutaneously injected into the right flank of
the mice, immediately followed by inoculation of 0.1 ml. of the Ehrlich tumour
ascitic fluid containing 5 x 106 cells into the same site. In the control, isotonic
saline was injected before the tumour inoculation.
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Hydrocortisone acetate (HCA), obtained from Nippon Merck Banyu Co. Ltd..
in the form of aqueous suspension, was daily injected subcutaneouslv into the
left buttock (1 mg./day/mouse).
After killing, the subcutaneous solid tumours thus produced were excised
and weighed. The results of the experiments were evaluated on the basis of
the average weight of tumour tissue in the experimental as compared with the
control group.
Chondroitin sulphate in the subcutaneous space ofmice was checked as follow%N-s.
From 1 to 3 days after subcutaneous injection of 1 ml. of 2 0 chondroitin sulphate
solution into the back of mice, the back skin was incised and subcutaneous tissue
was exposed. A piece of filter paper (Toyo Filter Paper No. 51, Toyo Roshi Co.
Ltd., Tokyo) was put on the exposed area in order to absorb the tissue fluid, and
then the paper was stained with toluidine blue solution by means of Leitner and
Kerby's (1954) method. Afterwards, the subcutaneous tissues so exposed were
excised and prepared for microscopical examination.
RESULTS
Solid Ehrlich tumours were produced by subcutaneous injection of ascitic
tumour cells with and without the pretreatment of 1 ml. of 2% chondroitin
sulphate solution. The average tumour weight was greater in the chondroitin
sulphate treated group than in the control group, and the difference between
them was statistically significant.
Influence of HCA on the tumour growth was studied in relation to the growth
promoting activity of chondroitin sulphate. Table I shows that chondroitin
sulphate treatment promoted, and HCA treatment inhibited, the growth of
tumour, and also that the chondroitin sulphate treatment showed a tendency
to counteract the inhibitory effect of HCA on the tumour growth. though the
activity of chondroitin sulphate was influenced by the duration and period of
HCA treatment.
When HCA treatment was started simultaneously with tumour inoculationl,
the promoting activity of chondroitin sulphate on the growth of the tumour
was not detected (Table I-A), whereas some effect was seen when HCA treatment
was started one day after tumour inoculation (Table I-B). In the case of pre-
treatment by HCA, i.e., when the daily injection of HCA was continued for 6
days preceding tumour inoculation but not after, no stimulatory effect of chon-
droitin sulphate on the growth of tumour was observed in the early stage of
tumour development. As shown in Table I-C, no difference in tumour weight
was observed between chondroitin sulphate treated and control group 4 days
after tumour inoculation, but after 7 days there appeared significant difference
between them.
Three ml. of 2% chondroitin sulphate solution accelerated more markedly
the growth of tumour than did 1 ml. of the same solution, when the treatment
was done before tumour inoculation, as shown in one of my previous papers
(Takeuchi, 1966). Table II shows that the correlation between chondroitin
sulphate dose and the increase in tumour growth was also influenced by HCA
treatment. It seemed to indicate that the inhibitory effect of HCA became
more prominent as the dose of chondroitin sulphate increased, i.e., it Nas only
when HCA treatment was not carried out that the difference of tumour weight
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TABLE I.-Effect ofHCA on the Growth-Promoting Activity of
Chondroitin Sulphate on Solid Ehrlich Ascites Tumour
A. HCA treatment was started immediately after tumour inoculation.
Days after Chondroitin
tuimour HCA sulphate Number Tumour weight
inoculation treatmcnt treatment of mice mean±S.E. (mg.) P
3davs . - . + . 8 . 475+ 58-7,P <0001
+ . + . 8 . 55± i -
-. - . 8 . 215± 9 093-P
+ . . 8 55± 4
6 (lays . - . + . 9 11834-184 0,005 <P <0-01
+ . + 10 . 361± 60
-. - . 9 . 566± 67 005 -<P<0l1
+ . . 9 225± 29
7 days . - . + . 10 . 1760 248 0 02 <P <0 05
+ + . 10 . 384 32
-. - . 10 . 1030±202' 0-6<P <07
+ . . 10 . 446 4- 52
B. HCA treatment was started on the next day after tumour inoculation.
7days . - . + . 9 . 1811±218 -.P<0-001
+ . + . 10 . 710±120 ><
10 830±134 0-01 -P 0 02
+ . . 10 . 255 ± 35
C. HCA treatment was continued for 6 days before tumour inoculation.
4 (lays . - . + 10 . 430± 68 0-001 <P <0 00.5
+ . + . 9 116±15k
10 . 235± 245>6 <P <0 7
+ . . 8 . 107± 12
7 dlays . - . + . 10 . 1640±182 7 0005<P 001
+ . + . 9 . 506±56/
- . - .10 . 920±150[0.005 IP 0 01
+ . . 10 . 288± 28
HCA treatment (+): 0-1 ml. of hydrocortisone acetate was injected (1 mg./day).
HCA treatment (-): 0-1 ml. of Saline was injected.
Chondroitin sulphate treatment (+): 1 ml. of 2% caondroitin sulyhate solution was injected
before tumour inoculation.
Chondroitin sulphate treatment (-): 1 ml. of saline was injected before tumour inoculation.
P: The evaluation was based on the Student's t-test.
TABLE II.-Effect of HCA on the Promoting Activity of Different Amounts of
Chondroitin Sulphate on the Growth of Tumour on the 7th day after Tumour
Inoculation.
Nutmber HCA Tunmour weiglht
of mice Treatment meaii-LS;.E£. (mng.) P
Conitrol (I ml. of saline) . 8 . - . 8061- 70
9 . + . 4104 62 P -0.001
1 ml. of 2% Chon(droitin suill)hate 8 . - 1612± 180 00 1l -- 0 02
10 . + . 870±142 001 --P -) 002
3 ml. of 2% Chondroitin sulphate . 8 - 2312+4198 03 P (0)4
9 . + . 1032±118-
1 ml. or 3 ml. of 2% chondroitin sulphate solution was injected into the subcutaneous space of
mice, immediately followed by tumour inoculation into the same site. HCA treatment was started
on the-next day after tumour inoculation.
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between the 1 ml. chondroitin sulphate group and the 3 ml. group was observed
but when it was, the difference was statistically insignificant.
The presence of chondroitin sulphate in the subcutaneous space of mice was
demonstrated on the filter paper as a metachromatically coloured spot. In the
case of HCA treated as well as untreated mice chondroitin sulphate was seen for
2 days after injection at the injected site in the subcutaneous space of mice. On
the third day, chondroitin sulphate was detected in the HCA treated group, but
not in the control group of chondroitin sulphate treated mice. No trace of
chondroitin sulphate was detected in those mice which had not received chondroitin
sulphate pretreatment.
DISCUSSION
The present data indicate that chondroitin sulphate treatment counteracts
the effect of HCA on the growth of solid Ehrlich ascites tumour. When HCA
treatment was started one day after tumour inoculation, the promoting effect
of chondroitin sulphate on tumour growth was observed to some extent, whereas
no stimulation was seen when HCA treatment was begun immediately after
tumour inoculation. This result indicates that the first 24 hours following
tumour inoculation is quite important for the growth-promoting activity of
chondroitin sulphate.
When HCA was given daily before tumour inoculation but not after, no effect
of chondroitin sulphate was seen in the early stage of the tumour growth. But
after one week there appeared a significant difference in tumour weight between
the chondroitin sulphate treated and the control group. This result indicates
that the effect of chondroitin sulphate for the growth of tumour lasted for a
relatively long period, even though chondroitin sulphate could not be detected
in the subcutaneous space of mice by means of filter paper 3 days after injectiol.
When HCA treatment was not included, the difference in tumour weighlt
between the 3 ml. chondroitin sulphate group and the 1 ml. group was statistically
significant, but when HCA was given the difference became insignificant (Table
II). It seems that the inhibitory effect of HCA becomes more remarkable as
the tumour grows vigorously. The same tendency was also observed in the
relations between the age and sex and the effect of HCA upon the tumour growth.
i.e., the inhibitory effect of HCA was very remarkable in young and old mice in
which tumour growth was more rapid than in the middle aged mice (Takeuelli
et al., 1965).
The exact mechanism of the action of chondroitin sulphate and HCA on the
growth oftumour cannot be deduced from the data obtained in these experiments.
However, it is quite conceivable that chondroitin sulphate helps tumour growtlh
by protection of the surface of tumour cells and promotion of the exchange of
their metabolites, and on the other hand that HCA inhibits tumour growth by
counteracting the promoting effect of chondroitin sulphate for the passage of
metabolites.
SUMMARY
Using solid Ehrlich ascites tumour developed subcutaneously in SM mice.
the relation between the promoting activity of ehondroitin sulphate and the
inhibitory effect of hydrocortisone acetate (HCA) on the tumour growth was
studied.SOLID EHRLICH ASCITES TUMOUR 851
It was observed that the chondroitin sulphate treatment tends to counteract
the inhibitory effect of HCA on the tumour growth. But the growth-promoting
activity ofchondroitin sulphate was influenced by the time ofHCA administration.
The mechanism of the counteraction of chondroitin sulphate against the HCA
treatment was discussed.
The present author owes a debt of gratitude to Professor H. Tauchi for his
advice and encouragement, and also to Dr. M. Kodama, Aichi Cancer Centre
Research Institute, for fruitful discussions of the problems.
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